Combined modality therapy: Is it necessary for everyone? Journal Article
| Authors: | Porembka, M. R.; Weiser, M. R. |
| Article Title: | Combined modality therapy: Is it necessary for everyone? |
| Abstract: | Survival and relapse in rectal cancer are intimately associated with disease stage. Although surgery remains the primary treatment modality for rectal cancer, its limitations as an isolated curative treatment are well recognized. Trimodality therapy combining surgery, chemotherapy, and radiation has improved local recurrence rates and survival in patients with advanced rectal tumors (T3/4) or those with nodal involvement (N1/2). With the broad application of trimodality therapy, concern for over-treatment in select groups of patients exists. Current investigations are now focused on identifying subsets of favorable-risk patients who may benefit from tailored therapy and reducing exposure to unnecessary treatment-related risk. © 2013 Elsevier Inc. |
| Keywords: | cancer chemotherapy; cancer survival; bevacizumab; fluorouracil; multimodality cancer therapy; capecitabine; adjuvant therapy; cancer adjuvant therapy; cancer radiotherapy; treatment indication; multiple cycle treatment; continuous infusion; radiation injury; risk assessment; folinic acid; oxaliplatin; rectum cancer; fluoropyrimidine; rectum surgery; total mesorectal excision; randomized controlled trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); preoperative radiotherapy |
| Journal Title: | Seminars in Colon and Rectal Surgery |
| Volume: | 24 |
| Issue: | 3 |
| ISSN: | 1043-1489 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2013-09-01 |
| Start Page: | 151 |
| End Page: | 154 |
| Language: | English |
| DOI: | 10.1053/j.scrs.2013.03.008 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 October 2013" - "CODEN: SCRSF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work